These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2537687)

  • 21. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
    Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
    Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum pancreatic oncofetal antigen: its clinical usefulness for screening pancreatic cancer in combination with tests for other tumor markers.
    Homma T; Oguchi H; Kawa S; Nagata A; Furuta S
    Gastroenterol Jpn; 1983 Oct; 18(5):487-91. PubMed ID: 6197338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer.
    Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S
    Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
    Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
    Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer.
    Nishida K; Miyagawa H; Yoshikawa T; Kondo M
    Oncology; 1988; 45(3):166-71. PubMed ID: 3163417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CA 19-9 and pancreatic adenocarcinoma.
    Safi F; Beger HG; Bittner R; Büchler M; Krautzberger W
    Cancer; 1986 Feb; 57(4):779-83. PubMed ID: 3455839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value and limitations of neoplasm markers in the diagnosis of pancreatic carcinoma].
    Fabris C; Basso D; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Ferrara C; Scalon P; Naccarato R
    Recenti Prog Med; 1991 Mar; 82(3):166-72. PubMed ID: 2047559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic significance of cancer antigen 125, pancreatic oncofetal antigen, and carcinoembryonic antigen in malignant and tuberculous pleural effusions.
    Niwa Y; Shimokata K
    Jpn J Clin Oncol; 1986 Mar; 16(1):3-8. PubMed ID: 3009919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of adenocarcinoma-associated antigen YH206 levels in the pancreatic juice.
    Imai K; Ban T; Endo T; Hinoda Y; Sugiyama T; Hirane T; Yabana T; Hirata K; Wada T; Yachi A
    Gastroenterol Jpn; 1990 Feb; 25(1):112-6. PubMed ID: 2407594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers.
    Sawabu N; Toya D; Takemori Y; Hattori N; Fukui M
    Int J Cancer; 1986 May; 37(5):693-6. PubMed ID: 3457770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9.
    Haglund C; Lindgren J; Roberts PJ; Nordling S
    Int J Cancer; 1986 Dec; 38(6):841-6. PubMed ID: 3466871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical evaluation of a pancreatic oncofetal antigen (POA) in carcinoma of the pancreas].
    Hishinuma S; Takami H; Matsui J; Uematsu S; Baba H; Ogata Y; Abe O; Miyoshi K; Ishii T; Yamamori S
    Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1432-7. PubMed ID: 6097615
    [No Abstract]   [Full Text] [Related]  

  • 33. Diagnosis of pancreatic cancer by pancreatic oncofetal antigen (poa) in pure pancreatic juice.
    Nishida K; Kondo M; Jessen K; Classen M
    Hepatogastroenterology; 1981 Apr; 28(2):102-5. PubMed ID: 7216142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer.
    Beretta E; Malesci A; Zerbi A; Mariani A; Carlucci M; Bonato C; Ferrari AM; Di Carlo V
    Cancer; 1987 Nov; 60(10):2428-31. PubMed ID: 3478117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor markers of pancreatic carcinoma.
    Klavins JV
    Cancer; 1981 Mar; 47(6 Suppl):1597-601. PubMed ID: 6168354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody defines CA 19-9 in pancreatic juices and sera.
    Schmiegel WH; Kreiker C; Eberl W; Arndt R; Classen M; Greten H; Jessen K; Kalthoff H; Soehendra N; Thiele HG
    Gut; 1985 May; 26(5):456-60. PubMed ID: 3858206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The distribution and localization of the monoclonal antibody-defined antigen 19-9 (CA19-9) in chronic pancreatitis and pancreatic carcinoma. An immunohistochemical study.
    Makovitzky J
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1986; 51(6):535-44. PubMed ID: 2878526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen detection by the monoclonal antibodies CA 19-9 and CA 125 in normal and tumor tissue and patients' sera.
    Dietel M; Arps H; Klapdor R; Müller-Hagen S; Sieck M; Hoffmann L
    J Cancer Res Clin Oncol; 1986; 111(3):257-65. PubMed ID: 3460995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.